A general change of the platelet transfusion policy from apheresis platelet concentrates to pooled platelet concentrates is associated with a sharp increase in donor exposure and infection rates

Transfusion Medicine and Hemotherapy

Volumn 35, Issue 2, 2008, Pages 106-113

  Heuft, Hans Gert ^a   Mende, Wolfgang ^a   Blasczyk, Rainer ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Apheresis platelet concentrates; Donor exposure; Infection rates from apheresis platelet concentrates; Infection rates from pooled platelet concentrates; Pooled platelet concentrates

Indexed keywords

NEUTRALIZING ANTIBODY; THROMBOCYTE CONCENTRATE;

ADULT; BLOOD DONOR; DIAGNOSIS RELATED GROUP; FEMALE; HOSPITAL DEPARTMENT; HUMAN; INFECTION RATE; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; MEDICAL SCHOOL; PLASMAPHERESIS; POPULATION; PREVALENCE; RECIPIENT; REVIEW; SURGICAL PATIENT; THROMBOCYTE TRANSFUSION; VIRUS INFECTION;

EID: 42349094746     PISSN: 16603796     EISSN: None     Source Type: Journal    
DOI: 10.1159/000117788     Document Type: Review

References (39)

1. Walther-Wenke G, Doerner R, Montag T, Greiss O, Hornei B, Knels R, Strobel J, Volkers P, Däubener W; Working party on Bacteria Safety in Transfusion Medicine of the Advisory Board of the German Ministry of Health (Arbeitskreis Blut), Berlin, Germany: Bacterial contamination of platelet concentrates prepared by different methods: results of standardized sterility testing in Germany. Vox Sang 2006;90:177-182.
2. Seghatchian J, de Sousa G: Pathogen-reduction systems for blood components: the current position and future trends. Transfus Apher Sci 2006;35:189-196.
3. Schlenke P, Hagenah W, Andresen S, Bauhaus M, Sundin D, Lin L, Corash L, Wagner T, Kirchner H: Pathogen inactivated platelets using the Intercept™ blood system: clinical outcomes of the first single-centre trial in Germany (abstract). Transfus Med Hemother 2007;34(S1):24.
4. Goodrich RP, Edrich RA, Li J, Seghatchian J: The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci 2006;35:5-17.
5. Roth WK, Weber M, Buhr S, Drosten C, Weichert W, Sireis W, Hedges D, Seifried E: Yield of HCV and HIV-1 NAT after screening of 3.6 million blood donations in central Europe. Transfusion 2002;42:862-868.
6. Jarvis LM, Dow BC, Cleland A, Davidson F, Lycett C, Morris K, Webb B, Jordan A, Petrik J: Detection of HCV and HIV-1 antibody negative infections in Scottish and Northern Ireland blood donations by nucleic acid amplification testing. Vox Sang 2005;89:128-134.
7. Schrezenmeier H, Walther-Wenke G, Muller TH, Weinauer F, Younis A, Holland-Letz T, Geis G, Asmus J, Bauerfeind U, Burkhart J, Deitenbeck R, Forstemann E, Gebauer W, Hochsmann B, Karakassopoulos A, Liebscher UM, Sanger W, Schmidt M, Schunter F, Sireis W, Seifried E: Bacterial contamination of platelet concentrates: results of a prospective multicenter study comparing pooled whole blood-derived platelets and apheresis platelets. Transfusion 2007;47:644-652.
8. Boeck M, Rahrig S, Kunz D, Lutze G, Heim MU: Platelet concentrates derived from buffy coat and apheresis: biochemical and functional differences. Transfus Med 2002;12:317-324.
9. Krailadsiri P, Seghatchian J: Are all leucodepleted platelet concentrates equivalent? Comparisons of COBE LRS Turbo, Haemonetics MCS+ LD and filtered pooled buffy-coat-derived platelets. Vox Sang 2000;78:175-179.
10. Metcalfe P, Williamson LM, Reutelingsperger CP, Swann I, Ouwehand WH, Goodall AH: Activation during preparation of therapeutic platelets affects deterioration during storage: a comparative flow cytometric study of different production methods. Br J Haematol 1997;98:86-95.
11. The Trial to Reduce Alloimmunization to Platelets Study Group: Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N Engl J Med 1997;25;337:1861- 1869.
12. Slichter SJ, Davis K, Enright H, Braine H, Gernsheimer T, Kao KJ, Kickler T, Lee E, McFarland J, McCullough J, Rodey G, Schiffer CA, Woodson R: Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005;105:4106-4114.
13. Gurkan E, Patah PA, Saliba RM, Ramos CA, Anderson BS, Champlin R, de Lima M, Lichtiger B: Efficacy of prophylactic transfusions using single donor apheresis platelets versus pooled platelet concentrates in AML/MDS patients receiving allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2007;40:461-464.
14. Sweeney JD, Petrucci J, Yankee R: Pooled platelet concentrates: maybe not fancy, but fiscally sound and effective. Transfus Sci 1997;18:575-583.
15. Lopez-Plaza I, Weissfeld J, Triulzi DJ: The cost-effectiveness of reducing donor exposures with single-donor versus pooled random-donor platelets. Transfusion 1999;39:925-932.
16. Vassallo RR, Murphy S: A critical comparison of platelet preparation methods. Curr Opin Hematol 2006;13:323-330.
17. Greinacher A, Kiefel V, Klüter C, Kroll H, Pötzsch B, Riess H: Empfehlungen zur Thrombozytentransfusion der Thrombozytenarbeitsgruppe der DGTI, GTH und DGHO. Transfus Med Hemother 2006;33:528-543.
18. Greinacher A, Kiefel V, Klüter C, Kroll H, Pötzsch B, Riess H: Empfehlungen zur Thrombozytentransfusion der Thrombozytenarbeitsgruppe der DGTI, GTH und DGHO. Deutsche Med Wochenschr 2006;131:2675-2679.
19. Chambers LA, Herman JH: Considerations in the selection of a platelet component: apheresis versus whole blood-derived. Transfus Med Rev 1999;13:311-322.
20. Ness PM, Campbell-Lee SA: Single donor versus pooled random donor platelet concentrates. Curr Opin Hematol 2001;8:392-396.
21. Zeger G, Williams CT, Shulman IA: Single donor platelets: can we afford to use them? Can we afford not to use them? Transfus Sci 1997;18:585-588.
22. Heal JM, Blumberg N: Optimizing platelet transfusion therapy. Blood Rev 2004;18:149-165.
23. Medizinische Hochschule Hannover: Jahresbericht 2006. Präsident der Medizinischen Hochschule Hannover (Hrg.), Hannover, 2007.
24. Heuft HG, Goudeva L, Martens J, Schmitt-Thomssen A, Blasczyk R: The mobilization effect of platelet apheresis. Transfus Med Hemother 2006;33(S1):17.
25. Simons JN, Leary TP, Dawson GJ, Pilot-Matias TJ, Muerhoff AS, Schlauder GG, Desai SM, Mushahwar IK: Isolation of novel virus-like sequences associated with human hepatitis. Nat Med 1995;1:564-569.
26. Leary TP, Muerhoff AS, Simons JN, Pilot-Matias TJ, Erker JC, Chalmers ML, Schlauder GG, Dawson GJ, Desai SM, Mushahwar IK: Sequence and genomic organization of GBV-C: a novel member of the flaviviridae associated with human non-A-E hepatitis. J Med Virol 1996;48:60-67.
27. Linnen J, Wages J Jr, Zhang-Keck ZY, Fry KE, Krawczynski KZ, Alter H, Koonin E, Gallagher M, Alter M, Hadziyannis S, Karayiannis P, Fung K, Nakatsuji Y, Shih JW, Young L, Piatak M Jr, Hoover C, Fernandez J, Chen S, Zou JC, Morris T, Hyams KC, Ismay S, Lifson JD, Hess G, Foung SK, Thomas H, Bradley D, Margolis H, Kim JP: Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science 1996;271:505-508.
28. Loiseau P, Mariotti M, Corbi C, Ravera N, Girot R, Thauvin M, Portelette E, Mariette X, Roudot-Thoraval F, Benbunan M, Lefrere JJ: Prevalence of hepatitis G virus RNA in French blood donors and recipients. Transfusion 1997;37:645-650.
29. Roth WK, Waschk D, Marx S, Tschauder S, Zeuzem S, Bialleck H, Weber H, Seifried E: Prevalence of hepatitis G virus and its strain variant, the GB agent, in blood donations and their transmission to recipients. Transfusion 1997;37:651-656.
30. Heuft HG, Berg T, Schreier E, Kunkel U, Tacke M, Schwella N, Hopf U, Salama A, Huhn D: Epidemiological and clinical aspects of hepatitis G virus infection in blood donors and immunocompromised recipients of HGV-contaminated blood. Vox Sang 1998;74:161-167.
31. Berg T, Schreier E, Heuft HG, Naumann U, Neuhaus P, Huhn D, Hopf U: Hepatitis-G-Virus-Infektion: Epidemiologische Aspekte und klinische Relevanz. Dtsch Med Wochenschr 1997;122:268-274.
32. Seifried C, Weber M, Bialleck H, Seifried E, Schrezenmeier H, Roth WK: High prevalence of GBV-C/HGV among relatives of GBV-C/HGV-positive blood donors in blood recipients and in patients with aplastic anemia. Transfusion 2004;44:268-274.
33. Heringlake S, Ockenga J, Tillmann HL, Trautwein C, Meissner D, Stoll M, Hunt J, Jou C, Solomon N, Schmidt RE, Manns MP: GB virus C/ hepatitis G virus infection: a favourable prognostic factor in human immunodeficiency virus-infected patients? J Infect Dis 1998;177:1723-1726.
34. Kleinman S: Hepatitis G virus biology, epidemiology, and clinical manifestations: implications for blood safety. Transfus Med Rev 2001;15:201-212.
35. Murphy S: Platelets from pooled buffy coats: an update. Transfusion 2005;45:733-751.
36. Paul-Ehrlich-Institut: Bericht zur Meldung nach §21 Transfusionsgesetz für die Jahre 2001 und 2002. Bericht zur Meldung nach §21 Transfusionsgesetz für 2005 und 2006; www.pei.de/cln_043/DE/ home/de-node.html_nnn=true.
37. Willaert B: French haemovigilance data on platelet transfusion. Presentation of the Agence Francaise de Securite Sanitaire des Produits de Sante (AFSSAPS). Symposium of Platelet Usage and Platelet Product Selection, Hanover, Germany, June 18th, 2007; http://afssaps.sante.fr.
38. Goodnough LT: Platelet transfusion therapy. J Clin Apher 2001;16:43-48.
39. Wiwanitkit V: Hepatitis G virus RNA positivity among the voluntary blood donors: a summary. Ann Hepatol 2005;4:43-46.